Kalaris Therapeutics, Inc. (KLRS): who owns it and who trades it
As of Nov 16, 2026, KLRS insiders reported 1 open-market sale worth $12.9K and 2 purchases worth $6.2M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Brett R Hagen (Chief Accounting Officer), with $12.9K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Kalaris Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly bought. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns KLRS
56 funds and institutions reported KLRS shares worth $73.4M at the end of Q2 2026, about 79% of the company. The largest holder is Samsara Biocapital, LLC with 56.2%.
Funds and institutions (13F) 79%Everyone else 21%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Samsara Biocapital, LLC | 12.88M | 56.18% | $52.4M | -1% |
| Rtw Investments, LP | 1.30M | 5.67% | $5.3M | No change |
| Alyeska Investment Group, L.P. | 572,687 | 2.50% | $2.3M | No change |
| Siren, L.L.C. | 435,798 | 1.90% | $1.8M | No change |
| Vanguard Capital Management LLC | 398,712 | 1.74% | $1.6M | +56% |
| Ikarian Capital, LLC | 360,000 | 1.57% | $1.5M | No change |
| UBS Group AG | 262,131 | 1.14% | $1.1M | +4139% |
| Renaissance Technologies LLC | 149,351 | 0.65% | $608K | +126% |
| Marshall Wace, LLP | 139,201 | 0.61% | $567K | +105% |
| Geode Capital Management, LLC | 114,037 | 0.50% | $464K | +30% |
| ADAR1 Capital Management, LLC | 100,000 | 0.44% | $407K | No change |
| Woodline Partners LP | 100,000 | 0.44% | $407K | No change |
| WHI TRUST Co LLC | 97,493 | 0.43% | $397K | No change |
| Raymond James Financial Inc | 97,164 | 0.42% | $395K | -18% |
| Citadel Advisors LLC | 95,772 | 0.42% | $390K | New |
| Boothbay Fund Management, LLC | 92,261 | 0.40% | $376K | No change |
| Verdad Advisers, LP | 80,297 | 0.35% | $327K | New |
| Morgan Stanley | 72,326 | 0.32% | $294K | +89% |
| Vanguard Fiduciary Trust Co | 66,179 | 0.29% | $269K | +80% |
| BlackRock, Inc. | 54,442 | 0.24% | $222K | +51% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, KLRS insiders reported $6.2M of open-market purchases and $12.9K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | Samsara BioCapital, L.P. +4 | 10% owner | Purchase | 244,300 | $4.83 | $1.2M | Form 4 |
| Mar 20, 2026 | Brett R Hagen | Chief Accounting Officer | Sale | 1,915 | $6.72 | $12.9K | Form 4 |
| Dec 18, 2025 | Samsara Opportunity Fund, L.P. +4 | 10% owner | Purchase | 479,847 | $10.42 | $5M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Samsara Opportunity Fund, L.P. | 10% owner | $5M | – | Dec 18, 2025 |
| Samsara BioCapital, L.P. | 10% owner | $1.2M | – | May 20, 2026 |
| Brett R Hagen | Chief Accounting Officer | – | $12.9K | Mar 20, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
KLRS short interest
Low short interest. 1.5% of KLRS shares are sold short: about 1 share in 65. Over the last 12 reports the number of shares short went down 54%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 366,632 KLRS shares were sold short, 1.5% of the shares outstanding, up 19.7% from the report before. At the average daily volume of 67,573 shares, buying them all back would take about 5.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 366,632 | 1.54% | +20% | 67,573 | 5.4 |
| Oct 15, 2026 | 306,400 | 1.29% | -8% | 88,628 | 3.5 |
| Sep 30, 2026 | 331,876 | 1.39% | +4% | 72,771 | 4.6 |
| Sep 15, 2026 | 318,361 | 1.34% | -8% | 60,932 | 5.2 |
| Aug 31, 2026 | 345,990 | 1.45% | -12% | 49,090 | 7.0 |
| Aug 14, 2026 | 393,339 | 1.65% | -4% | 63,863 | 6.2 |
| Jul 31, 2026 | 411,651 | 1.80% | -21% | 1.05M | 1.0 |
| Jul 15, 2026 | 520,187 | 2.27% | +4% | 44,656 | 11.7 |
| Jun 30, 2026 | 502,578 | 2.19% | -34% | 93,575 | 5.4 |
| Jun 15, 2026 | 762,669 | 3.33% | -5% | 69,947 | 10.9 |
| May 29, 2026 | 801,523 | 3.50% | -0% | 77,879 | 10.3 |
| May 15, 2026 | 804,374 | 3.51% | -0% | 101,925 | 7.9 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Kalaris Therapeutics company events
Kalaris Therapeutics filed 12 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Aug 11, 2026ResultsReleased financial results. Filing
- Jul 20, 2026LeadershipThe Board of Directors of Kalaris Therapeutics, Inc. appointed Liisa Bayko as Chief Financial Officer and Treasurer of the Company, effective as of July 20, 2026. Filing
- Jul 17, 2026AnnouncementThe Company issued a press release announcing positive additional data from its Phase 1a SAD clinical trial of TH103 in treatment-naïve patients with nAMD. Data from the expanded cohorts build on previously reported positive findings from the trial, with additional patients showing improvements in… Filing
- Jul 6, 2026LeadershipMorana Jovan-Embiricos, Ph.D., notified Kalaris Therapeutics, Inc. of her decision to resign as a member of the Company’s board of directors, effective immediately. Filing
- Jun 4, 2026VoteReported shareholder vote results. Filing
- May 12, 2026ResultsReleased financial results. Filing
- Apr 10, 2026LeadershipMatthew Gall notified Kalaris Therapeutics, Inc. of his decision to resign as the Chief Financial Officer of the Company, effective April 14, 2026. Filing
- Mar 17, 2026ResultsReleased financial results. Filing
- Mar 9, 2026AnnouncementShared information with investors. Filing
- Dec 18, 2025AgreementKalaris Therapeutics, Inc., a Delaware corporation, entered into a securities purchase agreement with certain institutional accredited investors, pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 4,200,000 shares of the Company’s common… Filing
- Dec 17, 2025AnnouncementThe Company issued a press release announcing initial data from its Phase 1a SAD trial of TH103 in treatment-naïve patients with nAMD. The data demonstrate that TH103’s engineered molecular properties translated into clinically meaningful improvements in vision and retinal anatomy, with early… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Kalaris Therapeutics financials
Famous investors that hold KLRS
2 of the 50 well-known investors we track reported holding KLRS in their latest 13F filing. The largest position is Jim Simons's, worth $511K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 176,863 | $511K | 0.0% | +18% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 39,219 | $113K | 0.0% | -59% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named KLRS in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 26, 2026 | Coastlands Capital LP | 13G | 5.7% |
| Oct 26, 2026 | Coastlands Capital LP | 13G | 5.7% |
Questions about Kalaris Therapeutics, Inc. (KLRS) stock
Who owns the most KLRS stock?
The largest reported owner of Kalaris Therapeutics, Inc. (KLRS) is Samsara Biocapital, LLC, with 56.2% of the company. In total, 56 funds and institutions reported holding KLRS at the end of Q2 2026, together about 79% of the shares. See the largest owners.
Are KLRS insiders buying or selling?
In the last 12 months, KLRS insiders reported 2 open-market purchases worth $6.2M and 1 sale worth $12.9K. The latest trade was on May 20, 2026. See every trade.
What is the short interest in KLRS?
As of Oct 30, 2026, 366,632 KLRS shares were sold short, 1.5% of the shares outstanding, up 19.7% from the report before. At the average daily volume of 67,573 shares, buying them all back would take about 5.4 trading days (days to cover). See the history.
Which famous investors hold KLRS?
2 of the 50 well-known investors we track reported KLRS in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $511K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.